Emactuzumab ELISA Kit (KDC25202)

Colorimetric

Plasma, Serum

Quantitative

0.31-5 μg/mL

0.156 μg/ml

CV<20%

80-120%

2-8 ℃

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Emactuzumab, also known as RG-7155, is a humanized monoclonal antibody developed by Genentech/Roche. It was designed to directly against the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R), which is also known as macrophage colony-stimulating factor receptor (M-CSFR) and Cluster of Differentiation 115 (CD115). Emactuzumab has been investigated in the treatment for the diseases including fallopian tube cancer, ovarian cancer, peritoneal cancer and solid tumors. The trail that emactuzumab combination regimen with selicrelumab (RG7876) in solid tumors is currently in Phase II.